MedPath

Effectiveness and safety of ledipasvir and sofosbuvir for patients infected with HCV genotype 1 in clinical practices

Not Applicable
Conditions
Chronic hepatitis C genotype 1
Registration Number
JPRN-UMIN000024007
Lead Sponsor
Kyushu University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
1000
Inclusion Criteria

Not provided

Exclusion Criteria

(1)Decompensated cirrhosis (Child B/C) (2)Autoimmune hepatitis or primary biliary cholangiris (3)eGFR<30 (4)Positivity for antibody to HIV

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Rates of Sustained virological response at 12 weeks after the end of treatment
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath